CNWK.DE co.don AG XETRA up 100.00% intraday 10 Feb 2026: volume surge may change valuation

CNWK.DE stock surged 100.00% intraday to €2.48 on XETRA on 10 Feb 2026 on a notable volume uptick. The move followed an early open at €1.20, a trading range of €1.20–€1.28 before the spike, and volume of 6,984 versus a 30-day average of 9,389. Traders cite short-covering and renewed attention to co.don AG’s pipeline in the biotechnology sector. We examine drivers, valuation, liquidity and what the surge means for short-term traders and longer-term investors.

CNWK.DE stock intraday price action

CNWK.DE stock closed intraday at €2.48, a €1.24 rise from the previous close of €1.24. The recorded change shows a 100.00% increase from the prior session. The session low and high before the spike were €1.20 and €1.28 respectively. This sharp move pushed the price above the 50-day average of €2.47 and 200-day average of €2.40, signaling an immediate re-test of multi-month resistance levels.

CNWK.DE stock volume and liquidity context

Volume reached 6,984 shares, below the average of 9,389, yet notable given the price doubling. Relative volume of 0.74 shows the move occurred on concentrated trade rather than broad market participation. Bid-ask depth can be thin for co.don AG on XETRA, increasing intraday volatility. Traders should expect wider spreads and cautious position sizing in low-liquidity sessions.

CNWK.DE stock fundamentals and valuation

co.don AG reports trailing EPS of -0.43 and a negative P/E of -5.82, reflecting losses at current earnings levels. Book value per share stands at €1.76, and price-to-book is 1.41. The company shows a strong current ratio of 3.97 and cash per share of €0.78, which supports short-term liquidity. Gross margin is high at 89.11%, but operating margin is negative at -173.95%, underlining R&D and operating investment pressures.

CNWK.DE stock technicals and Meyka AI grade

Meyka AI rates CNWK.DE with a score of 62.62 out of 100 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technicals show price above both the 50- and 200-day averages (€2.47 and €2.40), but daily volatility is high. Note these grades are model outputs and are not guaranteed or financial advice.

CNWK.DE stock catalysts, risks and sector view

Catalysts include regulatory updates, trial milestones, or partnership deals for co.don AG’s autologous cell therapies. Healthcare sector momentum is mixed; the broader German Healthcare index showed a 0.51% one-day move, keeping biotech-specific news decisive. Key risks are continued negative EPS, thin float, and event-driven swings. Institutional coverage is limited, so retail flows and news can rapidly move CNWK.DE stock.

CNWK.DE stock trading strategy and price targets

For active traders, watch intraday VWAP and the €2.40–€2.50 zone as immediate support and €3.49 as the 52-week high target. Longer-term investors should balance upside to trial or partnership news against operating losses. We set near-term technical resistance at €3.10 and immediate support at €1.60 for risk management.

Final Thoughts

Key takeaways: CNWK.DE stock moved 100.00% intraday to €2.48 on XETRA on 10 Feb 2026, on concentrated volume of 6,984 versus an average of 9,389. Fundamentals show negative EPS (-€0.43) and a negative P/E (-5.82), but a solid current ratio (3.97) and book value per share of €1.76 provide balance. Meyka AI’s forecast model projects a 12-month base target of €3.20, implying an upside of 29.03% from €2.48. A bull target at €3.50 implies 41.13% upside, while a bear case at €1.60 implies -35.48% downside. Forecasts are model-based projections and not guarantees. As an AI-powered market analysis platform, Meyka AI stresses risk control for low‑liquidity biotech names and recommends position sizing that reflects event risk and sector volatility.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.